Article Sidebar
Published:
Jul 11, 2024DOI:
10.4314/ahs.v24i2.11Keywords:
Article Details
While African Health Sciences has been freely accessible online there have been questions on whether it is Open Access or not. We wish to clearly state that indeed African Health Sciences is Open Access. There are key issues regarding Open Access needing clarification for avoidance of doubt:
- 1. Henceforth, papers in African Health Sciences will be published under the CC BY (Creative Commons Attribution License) 4.0 International. See details on https://creativecomons.org/)
- 2. The copyright owners or the authors grant the 3rd party (perpetually and in advance) the right to disseminate, reproduce, or use the research papers in part or in full, format/medium as long as:
- No substantive errors are introduced in the process
- Attribution of authorship and correct citation details are given
- The referencing details are not changed.
Should the papers be reproduced in part, this must be clearly stated.
- 3. The papers will be freely and universally accessible online in an easily readable format such as XML in at least one widely recognized open access repository such as PUBMED CENTRAL.
B. ABRIDGED LICENCE AGREEMENT BETWEEN AUTHORS AND African Health Sciences
I submitted my manuscript to African Health Sciences and would like to affirm that:
1.0 I am authorized by my co-authors to enter into these arrangements.
2.0 I guarantee, on behalf of self and co-authors:
- That the paper is original, and has not been published in any other peer-reviewed journal; nor is it under consideration by other journal (s). It does not infringe existing copyright or any other person’s rights
- That we are/I am the sole author(s) of the paper and with authority to enter into this agreement. My granting rights to African Health Sciences is not in breach of any other obligation
- That the paper contains nothing unlawful, or libelous. Nor anything that would constitute a breach of contract, confidence or commitment given to secrecy, if published
- That I/we have taken care to ensure the integrity of the article.
3.0 I and all co-authors, agree that the paper, if accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. (see https://creativecommons.org/)
Main Article Content
The impact of COVID-19 pandemic in tuberculosis diagnosis in sub-Saharan Africa: data from DREAM program in Mozambique
Abstract
Background: TB is a global emergency, COVID-19 reversed the trend in TB mortality reduction to 2017 levels. Mozambique is one of the highest-burden countries with 368 new cases per 100.000 population in 2020.
Objectives: This analysis aims to evaluate a TB diagnostic service in two Mozambican cities before and during the COVID-19 pandemic.
Methods: We reviewed routine activity data from two laboratories in Mozambique (Maputo and Beira) in the period 01/2018–08/2022. GeneXpert test was prescribed based on clinical suspicion. Data about the number of tests, results, and rifampicin resistance were collected.
Results: In the period 3,071 tests were conducted: 391 positive, and 32 rifampicin resistant. The number of positive samples was higher in Beira (20.2% vs 5%, OR 4[3.1-5.2]).
In Maputo, we observed a higher percentage of rifampicin-resistant samples (13.2%vs7%, OR 0.5[0.2-1.1]), but the overall prevalence of rifampicin resistance was higher in Beira (14.1‰vs6.6‰, OR 2.1[1.0-4.5]).
In 2020 and the first semester of 2021 a reduction in activity was observed, but positivity rates remained stable, with a slight increment starting in 2020.
Conclusions: Our data confirm the impact of the COVID-19 pandemic on TB diagnostic services but also highlight possible benefits in terms of diagnostic appropriateness in clinical centers.
Keywords: COVID-19 pandemic; tuberculosis diagnosis; sub-Saharan Africa; Mozambique.
